Hypercell Technologies is an Ithaca, New York biotechnology company developing rapid, on-premise molecular diagnostics and antibody-based therapeutics for detecting and managing biological contaminants in the food chain and livestock. Its portable, DNA-based platform — anchored by the HyperKit sample-prep product and a connected SaaS layer — delivers lab-accuracy pathogen results, including avian and swine influenza, in under an hour without a central laboratory. Founded in 2021 around University of Georgia research by Ralph Tripp and Leslie Patrick Jones, the company is an SOSV IndieBio and Plug and Play alum and in April 2026 signed its first U.S. distribution agreement with Crimson Chemicals.
1
Round
1
Industry
4
Tags
Oct 14, 2026
Latest raise
Funding activity · 1 round
Oct 14, 2026
$3M
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
